Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer

被引:26
|
作者
Pinto, AE [1 ]
André, S [1 ]
Laranjeira, C [1 ]
Soares, J [1 ]
机构
[1] CROL, Dept Patol Morfol, Inst Portugues Oncol Francisco Gentil, P-1099023 Lisbon, Portugal
关键词
breast cancer; cell cycle regulators; c-erbB-2; expression; cell proliferation markers; overall survival;
D O I
10.1080/00313020400011250
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aim: The biological impact of cell cycle regulatory proteins on breast cancer progression is widely recognised, although mostly unclear. The aim of this preliminary study was to investigate the correlations of several cell cycle modulators (p53, p21, pRb, and mdm2) and c-erbB-2 expression with cell proliferation markers (S-phase fraction [SPF] and Ki-67) and overall survival in breast cancer. Methods: The series comprised 50 women with stage I-II invasive ductal breast carcinoma (median follow-up 87 months), who were selected for their tumour proliferative characteristics (15 low, 15 high, and 20 intermediate proliferative tumours). Tumour differentiation was assessed following the Nottingham grading criteria. Cell cycle regulators, oestrogen receptor status, and Ki-67 index were analysed by immunchistochemistry on paraffin embedded material (cut-offs 10%). c-erbB-2 was evaluated according to a standardised immunohistochemical assay and borderline cases were confirmed by FISH analysis. Ploidy and SPF were determined by DNA flow cytometry on frozen samples. Chi-square test and Fisher's exact test were applied to analyse the statistical significance of data. Results: Positive immunostaining was observed in nine (18%) p53+, 30 (60%) p21+, 13 (26%) pRb+, and one (2%) mdm2+ cases. c-erbB-2 expression was considered positive in 11 (22%) cases. In the subset of patients dead of the disease, a high incidence of c-erbB-2 over-expression (7/10, 70%) was verified. In general, no significant correlations among cell cycle regulators or between the latter and histopathological or proliferative characteristics were found. Only the p53-/p21+ phenotype significantly correlated with low SPF (p=0.048), and p21 positivity showed a trend to be associated with low SPF (p=0.083). No statistically significant correlations between cell cycle inhibitors and clinical outcome were found. On the contrary, c-erbB-2 overexpression showed significant correlations with DNA aneuploidy (p<0.001), high SPF (p<0.001), high tumour grading (p=0.008), lack of oestrogen receptors (p=0.036), and poor overall survival (p<0.001). Conclusions: The results seem to indicate the lack of correlations of cell cycle regulatory proteins with cell proliferation markers and overall survival in breast cancer, in contrast to c-erbB-2 over-expression which was found to be associated with increased proliferation rate and worse prognosis.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [21] 家族聚集性肝癌组织p53、p21、C-erbB-2基因表达分析
    林源
    莫显伟
    广西医科大学学报, 2006, (01) : 94 - 95
  • [22] Status of p53, p21, mdm2, pRb proteins, and DNA methylation in gonocytes of control and γ-irradiated rats during testicular development
    Moréno, SG
    Dutrillaux, B
    Coffigny, H
    BIOLOGY OF REPRODUCTION, 2001, 64 (05) : 1422 - 1431
  • [23] Expression of p21/waf1 in oral squamous cell carcinomas - correlation with p53 and mdm2 and cellular proliferation index
    Ng, IOL
    Lam, KY
    Ng, M
    Regezi, JA
    ORAL ONCOLOGY, 1999, 35 (01): : 63 - 69
  • [24] Changes in cell cycle and expression of P53, MDM2 and P21 in SMMC-7721 cells irradiated by 12C6+ ions
    Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China
    不详
    Fushe Yanjiu yu Fushe Gongyi Xuebao, 2006, 5 (313-316):
  • [25] Deletion of p21 can not substitute for p53 loss in rescue of mdm2 null lethality
    Luna, RMD
    Amelse, LL
    ChavezReyes, A
    Evans, SC
    Brugarolas, J
    Jacks, T
    Lozano, G
    NATURE GENETICS, 1997, 16 (04) : 336 - 337
  • [26] Nuclear texture analysis and p53, p21 and mdm2 immunohistochemistry in superficial bladder cancer patients.
    Williamson, KE
    McCabe, N
    Anderson, NH
    Maxwell, P
    Kelly, JD
    Hamilton, P
    JOURNAL OF PATHOLOGY, 2000, 190 : 43A - 43A
  • [27] Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes
    Pfister, C
    Larue, H
    Moore, L
    Lacombe, L
    Veilleux, C
    Tetu, B
    Meyer, F
    Fradet, Y
    INTERNATIONAL JOURNAL OF CANCER, 2000, 89 (01) : 100 - 104
  • [28] Mdm2, p53, p21 and pAKT protein pathways in benign neoplasms of the salivary gland
    Freire Soares Marques, Yonara Maria
    Moura de Lima, Marina de Deus
    Alves, Sergio de Melo
    Soares, Fernando Augusto
    de Araujo, Vera Cavalcanti
    Pinto, Decio dos Santos
    Mantesso, Andrea
    ORAL ONCOLOGY, 2008, 44 (09) : 903 - 908
  • [29] Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality
    Oca Luna R.M.D.
    Amelse L.L.
    Chavez-Reyes A.
    Evans S.C.
    Brugarolas J.
    Jacks T.
    Lozano G.
    Nature Genetics, 1997, 16 (4) : 336 - 337
  • [30] p53 and MDM2 in germ cell cancer treatment response
    Oliver, RTD
    Shamash, J
    Berney, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3928 - 3928